XERS as reported
Xeris Biopharma Holdings, Inc. reported $315M of revenue over the trailing twelve months, +41% on the year before. 9 reported series are charted on this page, each one as filed.
$315M
Revenue, trailing twelve months · to Q1 2026 · +41% against the twelve months before
- Net Income
- $12M
Net Income · −127% year on year · trailing twelve months to Q1 2026
- Op Margin
- 11%
Op Margin · trailing twelve months to Q1 2026
- EPS
- $0.07
EPS · −123% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $315M | +41% | Q1 2026 |
| Net Income | $12M | −127% | Q1 2026 |
| EPS | $0.07 | −123% | Q1 2026 |
| Gross Margin | 86% | n/a | Q1 2026 |
| Op Margin | 11% | n/a | Q1 2026 |
| Net Margin | 3.4% | n/a | Q1 2026 |
| ROE | 520% | n/a | Q1 2026 |
| ROA | −2.6% | n/a | Q1 2026 |
| ROIC | 9.9% | n/a | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Xeris Biopharma Holdings, Inc. (XERS) - Revenue & ProfitRevenue & ProfitXeris Biopharma Holdings, Inc. (XERS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #12 of 28 by Smart Score